Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK3 |
Variant | T1022I |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | JAK3 T1022I lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). T1022I confers a gain of function on Jak3 as demonstrated by increased phosphorylation of Stat5 and Erk, and cytokine-independent growth in culture (PMID: 32639993). |
Associated Drug Resistance | |
Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 T1022I |
Transcript | NM_000215.4 |
gDNA | chr19:g.17830534G>A |
cDNA | c.3065C>T |
Protein | p.T1022I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047438786.1 | chr19:g.17830534G>A | c.3065C>T | p.T1022I | RefSeq | GRCh38/hg38 |
NM_000215 | chr19:g.17830534G>A | c.3065C>T | p.T1022I | RefSeq | GRCh38/hg38 |
NM_000215.4 | chr19:g.17830534G>A | c.3065C>T | p.T1022I | RefSeq | GRCh38/hg38 |
NM_000215.3 | chr19:g.17830534G>A | c.3065C>T | p.T1022I | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 T1022I | Advanced Solid Tumor | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) inhibited viability of transformed cells expressing JAK3 T1022I in culture (PMID: 32639993). | 32639993 |